Shirt a Phobia

Sample Page

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression.[2][1][3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.[1] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.[1][4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.[5]

See also

References

  1. ^ a b c d “BTRX 335140 – AdisInsight”. adisinsight.springer.com. Retrieved 2020-01-25.
  2. ^ “BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders”. BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
  3. ^ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). “Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)”. J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
  4. ^ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
  5. ^ a b Taylor, Nick Paul (2 January 2025). “Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%”. Fierce Biotech. Retrieved 7 March 2025.